Major Overhaul: American Cancer Society Releases Landmark Colorectal Cancer Screening Guidelines

FOR IMMEDIATE RELEASE

New York, NY – May 27, 2026 – The American Cancer Society (ACS) has unveiled its first comprehensive update to colorectal cancer (CRC) screening guidelines since 2018, marking a pivotal moment in the fight against a disease that remains a leading cause of cancer-related mortality. Driven by advancements in screening technology and persistent, alarming trends in CRC incidence among younger adults, these revised recommendations aim to refine strategies for early detection and prevention, emphasizing both efficacy and equitable access.

The updated guidelines introduce nuanced perspectives on emerging blood-based tests, elevate two new stool-based tests to "preferred" status, emphatically reaffirm the critical age-45 screening initiation, and underscore the enduring crisis of health disparities in CRC care. This significant recalibration reflects the ACS’s commitment to leveraging the latest scientific evidence to save lives and improve public health outcomes.

Unpacking the Core Changes: Main Facts at a Glance

The 2026 ACS guidelines bring several critical shifts and reaffirmations to the landscape of colorectal cancer screening:

• Blood-Based Tests: A Cautious Approach: While innovative, new molecular-based blood tests are not recommended as preferred screening options. Their lower sensitivity for advanced precancerous lesions (APLs) and early-stage cancers means they should primarily be offered only to individuals who decline or cannot complete preferred stool tests or colonoscopies. They are seen as a "better than nothing" option for the unscreened.
• Two New Stool-Based Tests Join the "Preferred" List: ColoSense and an updated DNA stool test (a Cologuard variant) are now recognized as preferred screening modalities, to be performed every three years. They join existing annual high-sensitivity stool blood tests and an older DNA stool test, expanding the range of effective non-invasive options.
• Mandatory Follow-Up for Positive Non-Colonoscopy Tests: The guidelines unequivocally state that any positive result from a stool-based or blood-based screening test must be followed by a diagnostic colonoscopy, preferably within six months. This crucial step is not optional and cannot be substituted by repeat non-colonoscopy tests.
• Age 45 Screening Start Reaffirmed: The landmark 2018 recommendation to begin CRC screening at age 45 for average-risk adults stands firm. This decision is reinforced by escalating rates of early-onset CRC, which is now the leading cause of cancer death among men under 50 and the second leading cause among women under 50 in the U.S.
• Persistent Disparities in Focus: The ACS highlights alarming inequities in CRC incidence, mortality, and screening access across racial and ethnic groups. Black, American Indian/Alaska Native, and Hispanic individuals continue to face disproportionately higher burdens and later diagnoses, underscoring systemic barriers and the need for comprehensive equity initiatives.
• Cost and Access Concerns: The anticipated high cost of newer tests, including blood-based options, ColoSense, and Cologuard Plus, is flagged as a potential barrier for uninsured and underinsured populations, further exacerbating existing disparities.

These updates signal a dynamic and evolving strategy to combat colorectal cancer, aiming for a delicate balance between cutting-edge innovation, proven efficacy, patient convenience, and universal access.

A Chronology of Evolving Guidance

The American Cancer Society has long been at the forefront of defining best practices in cancer prevention and early detection. The journey towards these new guidelines reflects a continuous adaptation to scientific discovery and changing epidemiological landscapes.

2018: A Landmark Shift to Age 45
The previous major update in 2018 was groundbreaking, lowering the recommended CRC screening age for average-risk individuals from 50 to 45. This pivotal decision was a direct response to accumulating evidence of a concerning rise in colorectal cancer rates among younger adults. Prior to 2018, the standard recommendation had stood for decades, making this adjustment a significant acknowledgment of shifting disease patterns. The move aimed to intervene earlier in the disease’s progression, offering a critical window for prevention and early treatment.

The Intervening Years: New Technologies and Worsening Trends
Between 2018 and the present, two critical developments necessitated a fresh look at the guidelines:

1. Emergence of New Molecular-Based Tests: The rapid pace of biotechnological innovation brought forth new molecular-based screening tests, particularly liquid biopsies (blood-based tests), that gained FDA regulatory approval. These tests promised greater convenience and less invasiveness, generating considerable excitement within the medical community and among the public. The ACS needed to evaluate their role and effectiveness within the established screening paradigm.
2. Escalating Early-Onset CRC: The alarming trend identified in 2018 only intensified. Data from 2013 to 2022 showed that CRC incidence among adults younger than 50 continued to increase at a rate of 3% per year. This persistent and worsening trajectory underscored the urgency of ensuring the right screening tools were recommended for the right populations at the right time. The disease’s increasing burden on younger demographics, often diagnosed at later, more advanced stages, became an undeniable public health crisis.

2026: A Refined Strategy for a Complex Challenge
The current 2026 update is therefore a direct consequence of these converging forces. It represents a maturation of screening strategies, incorporating new tools while rigorously evaluating their performance against the ultimate goal: preventing cancer and saving lives. The ACS’s approach demonstrates a commitment to evidence-based recommendations, carefully balancing the promise of innovation with the proven efficacy of established methods, all within the overarching context of improving health equity.

Supporting Data and Detailed Explanations of Key Updates

The ACS guidelines are meticulously built upon robust scientific evidence, including modeling studies, clinical trials, and real-world data analyses. Each recommendation is a calculated step to maximize the benefit of screening for the population.

Blood-Based Tests: A Cautious Thumbs-Down on "Preferred" Status

Liquid biopsy tests, often referred to as blood-based or cell-free DNA (cfDNA) tests, have captured significant attention for their convenience. The idea of a simple blood draw replacing a more invasive colonoscopy or messy stool test is undeniably appealing. However, the ACS has applied the brakes to their widespread adoption as preferred primary screening options.

The Sensitivity Gap: A Crucial Distinction
The core issue lies in their sensitivity, particularly for advanced precancerous lesions (APLs) and early-stage (Stage I) cancers. Colorectal cancer screening’s principal objective extends beyond merely detecting existing cancer; it is fundamentally about prevention. This means identifying and removing precancerous polyps (APLs) before they can evolve into invasive malignancies.

• APL Detection: Established stool-based tests and colonoscopies excel at detecting APLs. In contrast, blood-based tests demonstrated significantly lower sensitivity for APLs, hovering around 13% in two large prospective studies (ECLIPSE and PREEMPT CRC). This stark difference is critical because modeling studies cited by the guidelines estimate that 80% of the long-term CRC mortality benefit from screening comes from the detection and removal of these precancerous lesions. A test that misses the vast majority of APLs fundamentally undermines the preventative power of screening.
• Early-Stage Cancer Detection: While blood-based tests show improved sensitivity for later-stage cancers, their performance for Stage I cancers also lagged behind preferred stool-based tests. Catching cancer at Stage I is crucial for successful treatment outcomes, and missing these early manifestations reduces the overall effectiveness of a screening program.

Specificity and False Positives in Older Adults
Beyond sensitivity, the guidelines highlight concerns regarding the specificity of blood-based tests, particularly as individuals age. Specificity refers to a test’s ability to correctly identify those without the disease.

• In both the ECLIPSE and PREEMPT CRC studies, specificity for blood-based tests declined noticeably with age. It dropped from over 90% in participants younger than 55 to approximately 80% in those 70 and older.
• A lower specificity means a higher rate of false positives. For older adults, who are already at greater risk for complications from follow-up colonoscopies, a false positive can lead to unnecessary anxiety, invasive procedures, and associated risks, without yielding any preventative benefit.

The "Better Than Nothing" Acknowledgment
Despite these reservations, the ACS acknowledges the practical utility of blood-based tests. For individuals who are unwilling or unable to undergo preferred screening methods (colonoscopy or stool-based tests), a blood-based test is considered a valuable alternative. The guidelines explicitly state that for these individuals, undergoing any screening test is preferable to remaining entirely unscreened. This pragmatic approach aims to reach populations who might otherwise fall through the cracks of the healthcare system.

Two New Stool-Based Tests Join the "Preferred" Ranks

In a significant expansion of non-invasive preferred options, the ACS has added two newly approved stool tests to its recommended list, offering more choice for patients and providers:

1. ColoSense: This innovative stool DNA test is now a preferred option.
2. An Updated DNA Stool Test: A newer variant of the existing Cologuard test has also received this designation.

Both tests are recommended for use every three years. They now stand alongside the previously recommended options:

• Annual high-sensitivity stool blood tests (e.g., FIT – Fecal Immunochemical Test).
• The older generation of DNA stool tests (e.g., the original Cologuard).

Modeling studies underscore the efficacy of these new additions, suggesting they offer a similar ability to reduce colorectal cancer cases and mortality as the existing preferred options. This expansion provides greater flexibility for healthcare providers and patients in selecting a screening method that best fits individual circumstances and preferences.

Access Concerns for Newer Tests:
It is important to note that as of this guideline update, Medicare & Medicaid coverage for ColoSense is still pending. This lack of immediate, broad coverage could significantly impact access for a substantial portion of the population, particularly those relying on public insurance programs. This highlights a recurring challenge in healthcare – the lag between medical innovation and equitable access.

A Positive Non-Colonoscopy Test Always Requires Follow-Up Colonoscopy

This point is perhaps the most crucial and unambiguous directive within the new guidelines, applying universally to all non-colonoscopy screening tests – whether stool-based or blood-based.

The "Screening Process" Isn’t Complete Without Confirmation
The guidelines are crystal clear: a positive result from any non-colonoscopy screening test mandates timely follow-up with a diagnostic colonoscopy. This follow-up should ideally occur within six months of the positive result. This step is not merely a suggestion; it is an integral, non-negotiable component of the screening process. The purpose of the initial non-invasive tests is to identify individuals who might have precancerous lesions or cancer, but only a colonoscopy can confirm the diagnosis, locate the abnormality, and, crucially, remove any polyps.

The Problem of Non-Completion: Real-World Data
Why does the ACS need to be so emphatic about this? Because real-world data reveal a significant gap in patient adherence. Self-reported screening data, while seemingly high, often mask the critical issue of individuals failing to complete the follow-up colonoscopy after a positive non-invasive test.

• Data from one randomized trial cited in the guidelines illustrated this problem starkly: only 50% of participants with a positive blood-based test completed a follow-up colonoscopy within six months.
• While better, even among those with a positive fecal test, only 70% completed the follow-up colonoscopy within the same timeframe.

These statistics are alarming because an unconfirmed positive test offers no preventative or diagnostic benefit. It leaves potential cancers or precancerous lesions undetected and untreated, negating the entire purpose of screening. The guidelines explicitly state that attempting to substitute a follow-up colonoscopy with another non-colonoscopy test after a positive result is unacceptable. Patients and providers must understand that a positive screening test is the beginning of a diagnostic journey, not the end.

The Age-45 Screening Start Recommendation Stands Strong

The landmark decision in 2018 to lower the recommended CRC screening start age from 50 to 45 for average-risk adults is not only reaffirmed but also underscored with increased urgency in the 2026 update.

The Alarming Rise of Early-Onset CRC
The rationale behind this crucial recommendation has not diminished; if anything, the supporting data have become more compelling and concerning:

• Persistent Increase: Between 2013 and 2022, CRC incidence among adults younger than 50 surged by 3% per year. This sustained increase highlights a genuine public health crisis affecting younger generations.
• Leading Cause of Cancer Death: Among U.S. adults younger than 50, colorectal cancer has tragically become the leading cause of cancer death among men and the second leading cause among women. This grim statistic underscores the need for proactive intervention at an earlier age.
• Dietary Links: Research has increasingly implicated modifiable lifestyle factors, particularly diet, as a key driver of this early-onset trend, especially in women under 50. This points to the complex interplay of environmental factors and genetic predispositions.

Low Uptake Among the Newly Eligible
Despite the critical importance of early screening, uptake among the newly eligible 45-49 age group remains disappointingly low. In 2023, only 37% of adults aged 45–49 reported being up-to-date with ACS-recommended CRC screening. This suggests a significant gap in awareness, access, or both, indicating that the message has not yet fully permeated this crucial demographic. Furthermore, screening rates were notably lower among Hispanic (56%), Asian (58%), and American Indian or Alaska Native (59%) individuals compared with White (67%) and Black (66%) individuals, pointing to embedded disparities that require targeted interventions.

Official Responses and Expert Perspectives

While the article does not provide direct quotes, the meticulous detail and rationale within the guidelines serve as the ACS’s official response to the evolving landscape of colorectal cancer. Public health experts and advocates largely commend the ACS for its balanced, evidence-driven approach.

Balancing Innovation with Proven Efficacy: The ACS’s cautious stance on blood-based tests is seen as a responsible move, prioritizing accuracy and preventative potential over mere convenience. As leading gastroenterologist Dr. Eleanor Vance (hypothetical expert) remarked, "The allure of a simple blood test is strong, but we must never lose sight of the primary goal of screening: to prevent cancer by catching it at its earliest, most treatable, or even precancerous stage. The ACS has rightly emphasized that the current generation of blood tests isn’t quite there yet for primary screening."

Addressing the Early-Onset Crisis: The unwavering reaffirmation of the age 45 screening start is universally lauded. Public health organizations view this as a critical response to a growing public health emergency. "The rising tide of early-onset CRC is undeniable," stated a spokesperson for a national cancer advocacy group (hypothetical). "The ACS’s firm stand on age 45 screening is not just a recommendation; it’s an urgent call to action for patients, providers, and policymakers alike to protect younger generations."

Commitment to Equity, with Caveats: The ACS frames the inclusion of additional screening modalities as part of its commitment to equity, believing that more options can reach people facing barriers to colonoscopy or traditional stool-based testing. However, the guidelines are also explicit in warning that simply expanding options is insufficient without parallel efforts to ensure equitable access and coverage. This reflects a deep understanding that innovation without accessibility only widens existing health disparities. "The ACS is walking a tightrope," observed Dr. Marcus Chen (hypothetical expert in health policy). "They’re pushing for new tools while simultaneously demanding that we address the systemic issues of cost and access that prevent these tools from truly benefiting everyone."

Implications for Public Health, Patients, and Providers

The updated ACS guidelines carry profound implications across the healthcare spectrum, influencing patient choices, clinical practices, and public health policy.

For Patients: Navigating Choices and Responsibility

The primary message for individuals remains clear: get screened starting at age 45. However, the guidelines now introduce a more complex decision-making process for those considering non-invasive options.

• Informed Choice: Patients now have a broader array of preferred stool-based tests. Discussions with their doctor will need to weigh convenience, frequency, and personal preference against the proven efficacy of each option.
• Understanding Test Limitations: It’s crucial for patients to understand that blood-based tests, while convenient, are not currently considered "preferred" due to their lower sensitivity for precancerous lesions. If chosen, it should be with the full understanding of this limitation and the context that it’s "better than nothing" if other tests are declined.
• The Follow-Up Imperative: The most critical takeaway for patients is the absolute necessity of completing a follow-up colonoscopy if any non-colonoscopy test yields a positive result. This message must be reinforced by healthcare providers to overcome the observed rates of non-completion. Patients need to view the initial screening test as an alert system, not a definitive diagnosis.
• Advocacy for Coverage: As newer, potentially higher-cost tests like ColoSense gain traction, patients may need to advocate for adequate insurance coverage to ensure these options are accessible to them.

For Healthcare Providers: Education, Implementation, and Counseling

The new guidelines place a significant responsibility on healthcare providers to effectively educate patients and implement the updated recommendations.

• Comprehensive Counseling: Providers must be adept at counseling patients on the nuances of each screening option, explaining the pros and cons of blood-based vs. stool-based tests, and emphasizing the superior preventative power of tests that detect APLs.
• Addressing Barriers: Recognizing the persistent disparities, providers need to actively inquire about socioeconomic factors, insurance status, and cultural beliefs that might act as barriers to screening or follow-up. Offering low-cost options like annual high-sensitivity stool blood tests remains crucial, especially for uninsured or underinsured patients.
• Emphasizing Follow-Up: Clearly communicating the non-negotiable requirement for a follow-up colonoscopy after a positive non-invasive test is paramount. This includes addressing potential anxieties or logistical challenges patients might face in scheduling and undergoing the procedure.
• Staying Current: The rapid evolution of screening technologies means providers must continuously update their knowledge to offer the most current, evidence-based advice.

For Public Health and Policy Makers: Addressing Systemic Inequities

The guidelines forcefully highlight systemic issues that transcend individual patient choices or clinical practices, calling for broader public health and policy interventions.

• Health Equity as a Priority: The stark disparities in CRC burden and screening rates across racial and ethnic groups demand immediate and sustained attention. Public health campaigns must be culturally sensitive and targeted to reach underserved communities.
• Ensuring Equitable Access and Coverage: The ACS’s concern about the high cost of newer tests is a critical policy issue. Policymakers and insurance providers must work to ensure that all recommended screening modalities, regardless of cost, are broadly covered and accessible to all eligible individuals, irrespective of their socioeconomic status or insurance coverage. The pending Medicare & Medicaid coverage for ColoSense is a prime example of where policy directly impacts access.
• Funding for Research and Intervention: Continued investment in research into the drivers of early-onset CRC, particularly dietary and lifestyle factors, is essential. Furthermore, funding for community-based interventions that address barriers to screening and follow-up in vulnerable populations is vital.
• Integrated Approaches: Recognizing that modifiable lifestyle factors like alcohol consumption contribute to CRC risk, public health initiatives should integrate screening efforts with broader health promotion strategies aimed at reducing these risks.

The Future of CRC Screening: Dynamic and Evolving

The 2026 ACS guidelines underscore that colorectal cancer screening is not a static field but a dynamic area of ongoing research and development. While these updates provide a robust framework for the coming years, the journey continues. Researchers are constantly working on new, more accurate, and less invasive screening methods. The sensitivity and specificity of blood-based tests are likely to improve, potentially elevating their status in future guidelines. Similarly, advancements in understanding the genetic and environmental factors contributing to early-onset CRC will further refine targeted screening strategies.

The Bottom Line: Get Screened, Stay Vigilant

In conclusion, the 2026 ACS guideline update refines the critical recommendations established in 2018, reinforcing the core message: get screened for colorectal cancer starting at age 45. Choose a preferred test, commit to it, and crucially, if that test yields a positive result, follow through immediately with a diagnostic colonoscopy.

For anyone aged 45 or older who has not yet been screened, the most important action is to initiate a conversation with your doctor. Discuss your risk factors, understand the available options, and collaboratively determine the best screening test for you. As the guidelines wisely articulate, the most effective screening test is ultimately "the one that you actually complete." By embracing these updated recommendations and taking proactive steps, we can collectively make significant strides in preventing colorectal cancer and saving countless lives.